J T Holmlund
Overview
Explore the profile of J T Holmlund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mapuskar K, Vasquez Martinez G, Pulliam C, Petronek M, Steinbach E, Monga V, et al.
Redox Biol
. 2023 Jan;
60:102599.
PMID: 36640725
Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD,...
2.
Sonpavde G, Matveev V, Burke J, Caton J, Fleming M, Hutson T, et al.
Ann Oncol
. 2011 Nov;
23(7):1803-8.
PMID: 22112969
Background: AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)....
3.
Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, et al.
Ann Oncol
. 2004 Aug;
15(9):1413-8.
PMID: 15319248
Background: The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C alpha in patients with relapsed low-grade...
4.
Oza A, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, et al.
Gynecol Oncol
. 2003 Apr;
89(1):129-33.
PMID: 12694666
Objective: ISIS 5132 is a 20-base phosphorothioate DNA oligonucleotide against human c-raf kinase, a downstream effector of ras oncogene function. C-raf kinase is a molecule in the MAP kinase signaling...
5.
Holmlund J, Monia B, Kwoh T, Dorr F
Curr Opin Mol Ther
. 2001 Nov;
1(3):372-85.
PMID: 11713802
Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in...
6.
Cunningham C, Holmlund J, Geary R, Kwoh T, Dorr A, Johnston J, et al.
Cancer
. 2001 Sep;
92(5):1265-71.
PMID: 11571742
Background: Abnormal expression of Ras proteins frequently is found with oncogenic transformation making ras a promising therapeutic target. ISIS 2503 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically downregulates H-ras...
7.
Cunningham C, Holmlund J, Schiller J, Geary R, Kwoh T, Dorr A, et al.
Clin Cancer Res
. 2000 May;
6(5):1626-31.
PMID: 10815879
Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense...
8.
Yuen A, Halsey J, Fisher G, Holmlund J, Geary R, Kwoh T, et al.
Clin Cancer Res
. 1999 Dec;
5(11):3357-63.
PMID: 10589745
Protein kinase C (PKC) is an attractive target in cancer therapy. It is overexpressed in a variety of cancers, and nonspecific inhibitors of PKC have demonstrated antitumor activity. Antisense oligonucleotides...
9.
Nemunaitis J, Holmlund J, Kraynak M, Richards D, BRUCE J, Ognoskie N, et al.
J Clin Oncol
. 1999 Nov;
17(11):3586-95.
PMID: 10550158
Purpose: To determine the maximum-tolerated dose (MTD) and pharmacologic behavior of ISIS 3521 (ISI 641A), an antisense phosphorothioate oligonucleotide to protein kinase C-alpha. Patients And Methods: Thirty-six patients with advanced...
10.
Miller L, Korn E, Stevens D, Janik J, Gause B, Kopp W, et al.
Blood
. 1999 May;
93(10):3250-8.
PMID: 10233876
This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein) administered after high-dose carboplatin (CBDCA) treatment. Patients...